CG Oncology
CGON
162 hedge funds and large institutions have $1.97B invested in CG Oncology in 2025 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 77 increasing their positions, 28 reducing their positions, and 19 closing their positions.
175% more call options, than puts
Call options by funds: $21.7M | Put options by funds: $7.88M
175% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 28
111% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 19
14% more funds holding
Funds holding: 142 → 162 (+20)
14% more capital invested
Capital invested by funds: $1.74B → $1.97B (+$238M)
6.75% more ownership
Funds ownership: 92.84% → 99.59% (+6.8%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$33.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24.1M |
| 4 |
Morgan Stanley
New York
|
+$22.2M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$18.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$59.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$30.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.2M |
| 4 |
DM
Deerfield Management
New York
|
-$20.8M |
| 5 |
O
OrbiMed
New York
|
-$14.3M |
CGON Hedge Fund Activity: Q2 2025 in Review
162 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q2 2025, worth a combined $1.97B — up 14% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CGON positions and 19 closed out — a net gain of 21 holders — while 77 added to existing stakes and 28 trimmed.
The largest buyer was Bank of America, adding an estimated $33.6M. The largest seller was Marshall Wace, exiting entirely with an estimated $59.2M sold.
- 162 institutional investors held CG Oncology (CGON) as of Q2 2025, up from 142 in Q1 2025.
- Funds reported $1.97B of CG Oncology stock for Q2 2025, up 14% quarter-over-quarter.
- 40 funds opened new CG Oncology positions in Q2 2025 and 19 closed out, a net change of +21 holders.
- The largest CG Oncology buyer in Q2 2025 was Bank of America, an estimated $33.6M added.
- The largest CG Oncology seller in Q2 2025 was Marshall Wace, an estimated $59.2M sold.
Based on aggregated 13F filings for Q2 2025.